Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 16

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 16
---
 Common Warrants are subject to a beneficial ownership limitation of 4.99%, which                                                                                                   |

8

| limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result in the selling stockholder owning, after exercise, a number of shares of common                                                 
 stock in excess of the beneficial ownership limitation. Dr. Hedrick is the President, Chief Executive Officer and a director of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc., 2710 Reed Road, Suite 160, Houston, Texas 77051. |

| (10) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                                                           
 securities purchased by Mr. Andrew Sims in the May 2024 PIPE Financing: (i) 4,902 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 4,902 shares of common               
 stock issuable upon the exercise of Series B Common Stock Warrants, as well as 4,913 shares of common stock held by Mr. Sims and 25,444 shares of common stock underlying unvested options to purchase shares of common stock held by Mr. Sims           
 that will vest within 60 days of April 10, 2025. The Common Warrants are subject to a beneficial ownership limitation of 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Common Warrants that would result 
 in the selling stockholder owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. Mr. Sims is the Chief Financial Officer of Plus Therapeutics and his address is c/o Plus Therapeutics, Inc.,     
 2710 Reed Road, Suite 160, Houston, Texas 77051.                                                                                                                                                                                                         |

| (11) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                                                      
 securities purchased by Mr. Richard Hawkins in the May 2024 PIPE Financing: (i) 4,902 shares of common stock; (ii) 4,902 shares of common stock issuable upon the exercise of Series A Common Stock Warrants; and (iii) 4,902 shares of             
 common stock issuable upon the exercise of Series B Common Stock Warrants, as well as 6,286 shares of common stock held by Mr. Hawkins and 18,174 shares of common stock underlying un